1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Lotus Pharmaceutical Co., Ltd.

Lotus Pharmaceutical Co., Ltd.

TTWSE:1795
172.50
TWD
-3.50
(-1.99%)
14.35EPS
13.12P/E
49.68BMarket Cap
Nov 05Next Earn
Lotus Pharmaceutical Co., Ltd.
TWSE:1795
(Taiwan Stock Exchange)

Recent

price

172.50

P/E

ratio

13.12

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
12.36
11.31
11.29
13.85
12.6
23.17
24.78
26.97
26.99
39.73
44.13
49.57
56.14
64.91
70.97
78.8
108.98
Revenue per Share
0.32
-0.82
-4.32
-0.94
-2.41
0.44
-0.56
0.09
0.42
2.74
4.22
5.5
11.59
15.72
19.35
18.14
14.41
Basic EPS, GAAP
-1.85
-5.62
-2.57
-4.12
-6.88
2.34
2.4
-1.35
1.67
-2.83
-0.2
-5.86
2.49
-6.36
17.91
12.01
1.25
Free Cash Flow per Basic Share
0.09
0.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.36
1.94
3.47
4.7
5.84
- -
Dividend per Share
13.7
12.07
10.49
7.01
33.12
32.76
31.21
30.42
30.33
31.74
35.64
42.21
52.92
65.54
79.82
90.48
92.48
Book Value per Share
13.65
11.94
10.41
-0.71
-0.73
-0.96
-1.91
-5.3
-4.38
-4.54
-4
6.18
3.38
16.26
27.19
-127.46
-131.28
Tangible Book Value per Share
48
47
45
151
183
238
238
238
238
242
243
255
261
261
262
260
261
Basic Weighted Avg Shares
590
532
503
2,092
2,310
5,522
5,903
6,424
6,429
9,611
10,729
12,649
14,633
16,958
18,584
20,509
28,486
Sales/Revenue/Turnover
3.86
-27.41
-40.31
6.82
-18.84
8.13
4.14
8.53
6.93
12.49
15.03
18.42
28.07
28.89
32.38
28.75
24.49
Operating Margin (%)
27
44
68
96
163
297
307
361
392
592
710
759
937
1,211
1,283
1,536
2,085
Depreciation Expense
15
-38
-193
-143
-442
104
-134
22
99
663
1,027
1,403
3,021
4,106
5,066
4,720
3,766
Net Income, GAAP
57.62
- -
- -
- -
- -
47.1
580.5
72.38
24.2
21.47
21.05
24.95
23.34
19.54
20.35
17.46
22.59
Effective Tax Rate (%)
2.55
-7.22
-38.31
-6.81
-19.14
1.88
-2.27
0.34
1.55
6.9
9.57
11.09
20.64
24.21
27.26
23.01
13.22
Profit Margin (%)
578
68
116
779
1,865
2,494
1,234
2,310
1,456
2,621
1,900
4,007
4,768
8,129
9,660
9,574
8,137
Working Capital
307
- -
49
478
3,611
4,112
2,714
4,411
1,462
3,840
5,024
4,710
8,643
9,702
8,578
43,166
43,978
LT Debt
647
588
630
1,456
8,802
8,731
8,361
7,654
7,681
7,719
8,745
11,069
13,868
17,334
21,180
23,780
24,305
Total Equity
1.29
- -
- -
- -
- -
1.78
-8.63
1.16
3.03
8.58
9.11
10.27
15.28
14.92
14.78
9.01
10.05
Return on Invested Capital (%)
2.26
- -
- -
- -
- -
1.78
-11.21
0.39
2.85
7.64
9.31
9.84
16.47
17.62
17.31
10.29
11.55
Return on Capital (%)
2.73
-6.22
-31.66
-24.8
-10.5
1.32
-1.76
0.3
1.37
8.87
12.47
14.17
24.23
26.32
26.3
21
16.86
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,310
3,516
5,822
LT Borrowings
42,447
43,708
43,260
LT Finance Leases
719
755
718
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
263
263
263
Market Capitalization
73,421
53,703
49,682

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
26,453
25,896
25,659
Cash, Cash Equivalents & STI
7,740
6,195
6,325
Accounts Receivable, Net
6,678
8,192
8,542
Inventories
9,649
9,252
8,899
Total Current Liabilities
16,879
16,238
17,522
Payables & Accruals
- -
- -
- -
ST Debt
4,310
3,516
5,822
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.28%
22.26%
12.27%
Free Cash Flow
130.54%
409.5%
-33.32%
Net Income, GAAP
83.69%
40.88%
-6.82%
Sales/Revenue/Turnover
14.63%
13.88%
10.36%
Total Cash Common Dividend
- -
- -
23.38%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,198
4,743
5,234
4,409
18,584
2025
4,730
4,747
4,771
6,262
20,509
2026
8,644
8,809
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.96
5.09
5.98
4.21
19.35
2025
5.47
2.78
5.53
4.21
18.14
2026
2.18
2.47
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.7
2025
- -
- -
- -
- -
5.84
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Lotus Pharmaceutical Co., Ltd. Lotus Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of generic and novel pharmaceuticals, with a primary focus on high-barrier oncology drugs including oral anti-cancer tablets and hard/softgel capsules; complex generics in cardiology, nephrology, central nervous system disorders, women's health, anti-obesity treatments, and osteoporosis medications; as well as 505(b)(2) products, new chemical entities, and biosimilars developed through internal R&D and licensing partnerships. Founded in 1966 and headquartered at 17F, No. 277 Songren Road, Xinyi District, Taipei, Taiwan, the company operates manufacturing facilities certified by leading regulators such as the US FDA, EU EMA, Japan PMDA, China NMPA, and Brazil ANVISA, supporting a portfolio of over 250 commercial products and more than 100 projects in development or registration. It maintains a global presence through direct operations in Taiwan, South Korea, Singapore, Thailand, Vietnam, Malaysia, Philippines, Hong Kong, China, and Japan, with partnerships extending to Indonesia, Myanmar, Sri Lanka, Bangladesh, the United States, Europe, and Brazil, targeting patients and healthcare providers in these markets with affordable, high-quality medicines. In September 2025, Lotus Pharmaceutical entered a definitive agreement to acquire 100% equity interest in New Alvogen Group Holdings, Inc., which owns Alvogen US, a US-based specialty pharmaceutical company, for an enterprise value of up to US$2 billion in cash, preferred shares, and contingent earnouts, aiming to create a top 20 global specialty pharma player by doubling pro forma revenues and EBITDA, adding nearly 100 pipeline products including inhalation, long-acting injectables, and peptides, and gaining a dedicated US salesforce and FDA-approved manufacturing site. Taiwan's Department of Investment Review granted approval for the transaction in November 2025, positioning the deal for year-end closing pending final regulatory clearances and internal procedures. This acquisition builds on a decade-long partnership with Alvogen, enhancing Lotus' end-to-end platform across R&D, manufacturing, and commercialization in Asia and the US while expanding its specialty generics and differentiated offerings.